Merck & Co Inc

MRK

$112.52

+25.4% last 12 months

Ken Fisher Holding value: $1.39 Billion Jeremy Grantham Holding value: $344 Million Jim Simons Holding value: $298 Million Ray Dalio Holding value: $103 Million Ken Griffin Holding value: $86.8 Million Steven Cohen Holding value: $70.5 Million Prem Watsa Holding value: $19.5 Million Joel Greenblatt Holding value: $19.3 Million Mario Gabelli Holding value: $14.5 Million Tom Russo Holding value: $431 Thousand Tom Gayner Holding value: $0 Daniel Loeb Holding value: $0 Chris Davis Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 David Tepper Holding value: $0 Warren Buffett Holding value: $0

Market Cap

$281 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$81.28 - $119.65

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

21.6x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$2.81 (2.53%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $281 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $302 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $2.81 (2.53%)
1 Year Return Profit or loss of share price change plus dividend yield. +27.9%
52-Week High Highest share price in the last 52 weeks. $119.65
52-Week Low Lowest share price in the last 52 weeks. $81.28
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.3
Outstanding Shares The number of shares the company has issued and are held by stockholders. 2.54 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 6.47 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 21.6
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -62.53
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $5.12
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 5.11
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 6.25
Enterprise Value to Revenue Enterprise value divided by revenue 5.22
Enterprise Value to EBIT Enterprise Value divided by EBIT 17.58
Total Debt to Enterprise Value Total debt divided by enterprise value 0.1
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.66

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $57.9 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $41.9 Billion
EBIT Earnings before tax and interest payments. $17.2 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $13 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 22.52%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -34.5%
Return on Equity Equity divided by market cap. 27.82%
Return on Assets Indicates a company's profitability in relation to its total assets. 12.09%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 20.28%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About Merck & Co Inc

CEO: Kenneth Frazier

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Lilly(Eli) & Co
Lilly(Eli) & Co
Sanofi - ADR
Sanofi - ADR
GSK Plc - ADR
GSK Plc - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Novartis AG - ADR
Novartis AG - ADR
Abbott Laboratories
Abbott Laboratories
AMGEN Inc.
AMGEN Inc.

News

Merck’s KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

Merck’s KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluati...

Wallstreet:Online Wallstreet:Online, 2 days ago
3 Undervalued Dow Stocks to Buy Before Wall Street Does

3 Undervalued Dow Stocks to Buy Before Wall Street Does

Wall Street has fallen back in love with rapidly growing tech companies with huge cash hoards and/or tremendous leverage to the artificial intelligence (AI) ...

InvestorPlace InvestorPlace, 3 days ago
AstraZeneca''s Lynparza Gets FDA Approval For BRCAm Prostate Cancer

AstraZeneca''s Lynparza Gets FDA Approval For BRCAm Prostate Cancer

LONDON (dpa-AFX) - AstraZeneca PLC. (AZN) (AZN.L) and Merck & Co. Inc.''s (MRK) Lynparza in combination with Abiraterone and Prednisone or Prednisolone has r...

Finanz Nachrichten Finanz Nachrichten, 4 days ago
Prometheus Biosciences: 8.5% IRR And Closing In A Month

Prometheus Biosciences: 8.5% IRR And Closing In A Month

Merck has agreed to acquire Prometheus Biosciences for $200 per share in cash. With the deal expected to close in a month, see whether RXDX stock is a Buy.

Seeking Alpha Seeking Alpha, 5 days ago
Never miss a trade
To improve your user experience we use cookies.